Erich Schlick
Director/Board Member at SYMETIS SA
Network origin in Erich Schlick first degree
| Entity | Entity type | Industry | |
|---|---|---|---|
Wellington Partners GmbH
 Wellington Partners GmbH Investment ManagersFinance Wellington Partners GmbH (Wellington Partners) is an independent venture capital firm founded in 1991 by Rolf Christof Dienst. The firm is headquartered in Munich, with offices in Zurich, London, and Palo Alto.
34
| Private Company | Investment Managers | 34 |
Ruprecht-Karls-Universität Heidelberg
15
| College/University | Other Consumer Services | 15 |
Immatics US, Inc.
 Immatics US, Inc. BiotechnologyHealth Technology Immatics US, Inc. develops adoptive cell therapies (ACT) for the treatment of cancer. The company’s ACT therapies are intended to use human T-cells that have been multiplied outside the body before being infused into a cancer patient. It also offers XPRESIDENT, a target discovery engine that enables users to identify, quantify, and prioritize tumor-associated peptides that are recognized by T-cells. The company was founded by Harpreet Singh-Jasuja, Toni Weinschenk, Niels Emmerich, Hans-George Rammensee, Steffen Walter, Peter Brossart and Hansjorg Schild in June 2015 and is headquartered in Houston, TX.
11
| Subsidiary | Biotechnology | 11 |
Evolva SA
 Evolva SA Miscellaneous Commercial ServicesCommercial Services Evolva SA is a Swiss-headquartered, international pharmaceutical biotech company focused on the discovery and development of drugs based on its distinctive and proprietary genetic chemistry platform. The company was founded in Switzerland in 2004 based on US/Danish technology. Evolva is headquartered in Allschwil/Basel with operations in Denmark, India and the USA. The Company has raised CHF 38.2 million of equity to date and employs 75 persons of whom 30 are based in Allschwil. The firm's strategy and business approach is based on five pillars that offer a sustainable development path for creating a successful company, which include Building a balanced portfolio. Evolva focuses on orally available small molecules in the belief that they are more convenient for patients and more cost-effective both from manufacture and administration points of view for the society, focus on differentiated pharmaceutical products with major benefits. Focusing on cardiovascular/renal and infectious diseases. Together they cause more than 50% of all deaths worldwide. Most of the top 20 pharmaceutical companies are active in both sectors, and all are active in one of the two sectors - hence widening Evolva's opportunities to partner. Building technology platform as the source of this differentiation. Evolva finds different structures with different properties from those found by the 99% of the industry that focuses on synthetic chemistry or proteins. Openness to unusual markets. The biotech business model has changed. As well as the established markets new opportunities arise in emerging countries such as India and China, and in adjacent sectors such as treatments against potential bio-terrorist and bio-warfare agents and the production of pharmaceutical and industrial chemical intermediates. Cost-effective implementation. Evolva places different functions around the globe according to where local conditions best suit. This approach both reduces Evolva's cost base and increases access to revenues, partners and talent. Evolva sees revenues and partners as important because they provide additional flexibility, resources and talent. Also, they provide important opportunities to better understand, and better meet, the needs of current and future customers.
10
| Subsidiary | Miscellaneous Commercial Services | 10 |
Immatics Biotechnologies GmbH
 Immatics Biotechnologies GmbH Pharmaceuticals: MajorHealth Technology Immatics Biotechnologies GmbH operates as a biopharmaceutical company that develops anti-cancer immunotherapy products. The firm specializes in the discovery and development of immunotherapy products against cancer. It develops IMA901, a combination of multiple tumor-associated peptides (TUMAPs) for the treatment of renal cell carcinoma. The company was founded by Harpreet Singh, Toni Weinschenk, Niels Emmerich, Hans Georg Rammensee, Hansjörg Schild, and Peter Brossart in 2000 and is headquartered in Tübingen, Germany.
10
| Subsidiary | Pharmaceuticals: Major | 10 |
NBE-Therapeutics AG
 NBE-Therapeutics AG BiotechnologyHealth Technology NBE-Therapeutics AG operates as biotechnology company. It develops next-generation ADCs improving treatment options for cancer patients. The company was founded by Ulf Grawunder in 2012 and is based in Basel, Swizerland.
7
| Subsidiary | Biotechnology | 7 |
Sensimed SA
 Sensimed SA Medical SpecialtiesHealth Technology Sensimed SA develops non-invasive soft contact lens-based solutions. It offers solutions to monitor fluctuations in intraocular pressure continuously. The company was founded by Matteo Leonardi and Sacha Cerboni in 2003 and is headquartered in Lausanne, Switzerland.
4
| Subsidiary | Medical Specialties | 4 |
| Subsidiary | Biotechnology | 1 |
Chart of Companies connected to the second degree
Multi-company connection
Companies connected to Erich Schlick via their personal network
| Company | Sector | Related people | Main position |
|---|---|---|---|
| 2INVEST AG | Financial Conglomerates | Director/Board Member Director/Board Member | |
| BASF SE | Electrical Products | Corporate Officer/Principal Human Resources Officer Corporate Officer/Principal | |
MedImmune Ltd.
 MedImmune Ltd. BiotechnologyHealth Technology MedImmune Ltd. engages in research, development and exploitation of products in the field of molecular engineering. The company was founded on December 11, 1989 and is headquartered in Cambridge, the United Kingdom. | Biotechnology | Chief Executive Officer Director/Board Member | |
| AC IMMUNE SA | Pharmaceuticals: Major | Director/Board Member Director/Board Member Corporate Secretary | |
CureVac SE
 CureVac SE BiotechnologyHealth Technology CureVac SE engages in the development of tumor immunotherapy. Its pipeline include mRNA-based Cancer Immunotherapies; Protein-based therapies; and mRNA-based Prophylactic Vaccines. The company was founded by Ingmar Hoerr, Florian von der Mülbe, Hans Georg Rammensee, Günther Jung, and Steve Pascolo in 2000 and is headquartered in Tübingen, Germany. | Biotechnology | Director/Board Member Director/Board Member | |
eWise Group, Inc.
 eWise Group, Inc. Packaged SoftwareTechnology Services eWise Group, Inc. provides financial software solutions. It products include money manager, personal data vault, connected insights and resources. The company was founded by Alexander Grinberg in 2000 and is headquartered in Centennial, CO. | Packaged Software | Director/Board Member Director/Board Member | |
| University of Freiburg | College/University | Corporate Officer/Principal Graduate Degree | |
Knoll AG
 Knoll AG Pharmaceuticals: MajorHealth Technology Part of BASF SE, Knoll AG develops pharmaceuticals. The company is based in Haren, Germany. | Pharmaceuticals: Major | Chairman Chief Executive Officer General Counsel | |
Atlas Venture Advisors, Inc.
 Atlas Venture Advisors, Inc. Investment ManagersFinance Atlas Venture Advisors Inc (Atlas Venture Advisors) is a venture capital firm founded in 1980 by Christopher Julian Spray. The firm is headquartered in Cambridge, Massachusetts. | Investment Managers | Corporate Officer/Principal Corporate Officer/Principal | |
| VALERIO THERAPEUTICS | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
| INSEAD | College/University | Masters Business Admin Masters Business Admin Masters Business Admin | |
| University of California, Berkeley | College/University | Graduate Degree Masters Business Admin | |
ESBATech, a Novartis Co. GmbH
 ESBATech, a Novartis Co. GmbH Miscellaneous Commercial ServicesCommercial Services ESBATech AG develops antibody fragment therapeutics. The firm's antibody fragment is derived from human antibody fragment scaffolds. It develops Immuna, an antigen-independent platform to screen, select, and optimize highly-stable and soluble, single-chain antibody fragments. The company was founded by Dominik Escher in September 1998 and is headquartered Schlieren, Switzerland. | Miscellaneous Commercial Services | Director/Board Member Director/Board Member | |
| HEIDELBERG PHARMA AG | Pharmaceuticals: Major | Director/Board Member Chairman | |
EnOcean GmbH
 EnOcean GmbH Electronic Production EquipmentElectronic Technology EnOcean GmbH develops and provides patented self-powered wireless technology. It manufactures and markets maintenance-free wireless sensor solutions for use in buildings and industrial installations. The firm's solutions are based on miniaturized energy converters, ultra-low-power electronic circuitry, and reliable wireless. Its products include accessories, software and firmware. The company was founded by Andreas Schneider and Frank Schmidt in 2001 and is headquartered in Oberhaching, Germany. | Electronic Production Equipment | Director/Board Member Director/Board Member Director/Board Member | |
Swyx Solutions GmbH
 Swyx Solutions GmbH Packaged SoftwareTechnology Services Swyx Solutions GmbH develops and provides software based internet protocol telephony solutions. Its products include unified communications and case studies, third party products and SIP-provider. The firm also offers communication software, phones, protocol and update services. The company was founded by Wolfgang Schröder, Ralf Ebbinghaus, Uwe Sauerbrey and Frank Heidemann in 1999 and is headquartered in Dortmund, Germany. | Packaged Software | Director/Board Member Chairman | |
| Technical University of Denmark | College/University | Graduate Degree Doctorate Degree | |
| University of Gottingen | College/University | Undergraduate Degree Corporate Officer/Principal | |
| Eberhard Karls Universität Tübingen | College/University | Doctorate Degree Doctorate Degree Doctorate Degree Corporate Officer/Principal Doctorate Degree | |
| University of Basel | College/University | Doctorate Degree Graduate Degree Doctorate Degree | |
| Technical University of Berlin | College/University | Graduate Degree Doctorate Degree | |
| Freie Universität Berlin | College/University | Doctorate Degree Graduate Degree Doctorate Degree | |
| University of Geneva | College/University | Masters Business Admin Doctorate Degree | |
| Swiss Federal Institute of Technology | College/University | Doctorate Degree Doctorate Degree Graduate Degree | |
| University of Lausanne | College/University | Doctorate Degree Graduate Degree | |
| Philipps University of Marburg | College/University | Chairman Graduate Degree | |
Amgen Rockville, Inc.
 Amgen Rockville, Inc. BiotechnologyHealth Technology Amgen Rockville, Inc. develops and commercializes antibody-based products. Its product development pipeline includes novel antibodies generated with its BiTE antibody platform, as well as conventional monoclonal antibodies. The company was founded in 1993 and is headquartered in Rockville, MD. | Biotechnology | Corporate Officer/Principal Chief Tech/Sci/R&D Officer | |
| Ludwig-Maximilians-Universität München | College/University | Undergraduate Degree Doctorate Degree Graduate Degree Doctorate Degree Doctorate Degree Undergraduate Degree | |
dievini Hopp BioTech holding GmbH & Co. KG
 dievini Hopp BioTech holding GmbH & Co. KG Investment ManagersFinance dievini Hopp BioTech holding GmbH & Co. KG operates as a private investment and consulting firm. It invests in companies related to the life and health sciences. It focuses with companies that diagnoses and provides therapy in the fields of oncology, neurology, infectious diseases, cell therapy and drug delivery systems. The company is headquartered in Walldorf, Germany. | Investment Managers | Private Equity Investor Founder | |
| Febit, Inc. | Director/Board Member Chairman | ||
| EVOLVA HOLDING SA | Food: Specialty/Candy | Director/Board Member Corporate Officer/Principal Director/Board Member Director/Board Member Chief Executive Officer | |
| dievini Verwaltungs GmbH | Chief Executive Officer Chief Executive Officer | ||
Molecular Health GmbH
 Molecular Health GmbH Miscellaneous Commercial ServicesCommercial Services Part of Posbelduf Biotech AG, Molecular Health GmbH is a German management consulting company. The company is based in Heidelberg, Germany. The company was founded in 2004 by Friedrich von Bohlen und Halbach. Friedrich von Bohlen und Halbach has been the CEO since 2004. | Miscellaneous Commercial Services | Chief Executive Officer Chairman | |
Molecular Health, Inc.
 Molecular Health, Inc. Packaged SoftwareTechnology Services Molecular Health, Inc. operates as a cloud-based healthcare decision support technology to enable evidence-based treatment decisions. The company was founded in 2004 and is headquartered in Boston, MA. | Packaged Software | Chairman Director/Board Member | |
Galecto Biotech ApS
 Galecto Biotech ApS Pharmaceuticals: MajorHealth Technology Galecto Biotech ApS provides galectin modulators for the treatment of severe diseases, including fibrosis and cancer. Its products include galectin-3 inhibitors, fibrosis and literature. The company was founded by Tariq Sethi, Hans Thalsgard Schambye, Ulf Jorgen Nilsson, and Hakon Leffler in 2011 and is headquartered in Copenhagen, Denmark. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
coramaze technologies GmbH
 coramaze technologies GmbH Medical SpecialtiesHealth Technology coramaze technologies GmbH operates as a medical device company which develops valve repair system. It offers mitramaze a novel concept for transcatheter mitral valve repair intended for treatment of inoperable patients suffering from severe functional mitral regurgitation. The company was founded by Laura Figulla and Till Neumann in 2013 and is headquartered in Munich, Germany. | Medical Specialties | Director/Board Member Director/Board Member | |
iOmx Therapeutics AG
 iOmx Therapeutics AG BiotechnologyHealth Technology iOmx Therapeutics AG develops immunotherapy treatments for cancer patients. It specializes in immuno oncology, drug development and cancer therapy. The company was founded by Nisit Khandelwal, Philipp Beckhove, Patrick Baeuerle, Sebastian Meier-Ewert and Elmar Maier in March 2016 and is headquartered in Munich, Germany. | Biotechnology | Director/Board Member Director/Board Member Director/Board Member | |
| GALECTO, INC. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
| IMMATICS N.V. | Biotechnology | Chairman Director/Board Member Director/Board Member Founder Corporate Officer/Principal Director of Finance/CFO Director/Board Member Corporate Officer/Principal Chief Operating Officer Corporate Officer/Principal Chief Tech/Sci/R&D Officer | |
High-Tech Gründerfonds Management GmbH
 High-Tech Gründerfonds Management GmbH Investment ManagersFinance High-Tech Gründerfonds Management GmbH (HTGF) is a venture capital firm founded in 2005. The firm is headquartered in Bonn, Germany. | Investment Managers | Private Equity Investor Private Equity Investor |
Statistics
International
| Germany | 29 |
| United States | 9 |
| Switzerland | 8 |
| Denmark | 5 |
| France | 3 |
Sectoral
| Health Technology | 19 |
| Consumer Services | 15 |
| Finance | 5 |
| Technology Services | 5 |
| Commercial Services | 5 |
Operational
| Director/Board Member | 432 |
| Corporate Officer/Principal | 154 |
| Chairman | 104 |
| Chief Executive Officer | 73 |
| Private Equity Investor | 60 |
Most connected contacts
| Insiders | |
|---|---|
| Eric Archambeau | 43 |
| Christof Hettich | 40 |
| Søren Lemonius | 39 |
| Friedrich von Bohlen und Halbach | 36 |
| Regina Hodits | 34 |
| Bo Jesper Hansen | 34 |
| Margret Suckale | 26 |
| Mohsen M. Sohi | 25 |
| Peter Chambré | 23 |
| Michael Heinz | 23 |
| Albert Joseph Markus | 22 |
| Chandra Paul Leo | 22 |
| Stuart Essig | 21 |
| Aniruddha Nazre | 21 |
| Jean-Philippe Tripet | 20 |
- Stock Market
- Insiders
- Erich Schlick
- Company connections
